01569: Evaluation of a Novel Drug to Treat Canine Cutaneous Lymphoma
Grant Status: Closed
Canine lymphoma is one of the most common cancers encountered in veterinary oncology. While most canine multicentric lymphoma patients initially respond to currently available chemotherapy protocols, response rates are considerably lower in patients with cutaneous T cell lymphoma (CTCL), and generally brief in duration. We previously demonstrated the effectiveness of the novel cancer drug GS-9219 (currently referred to as VDC-1101) in dogs with multicentric lymphoma, in which 100% of chemotherapy-na�ve and 60% of chemotherapy-relapsed patients experienced responses. One of the observed toxicities in VDC-1101 treated dogs was a skin change characterized by hair loss, redness and itching, implying significant delivery of VDC-1101 to the skin. Given the lack of durable effective therapy for canine CTCL, and the demonstrated anti-lymphoma activity and apparent skin accumulation of VDC-1101, evaluated the effectiveness of VDC-1101 in canine CTCL through the completion of a phase-II clinical trial. 11 dogs were evaluable; 45% of patients experienced objective improvement (1 complete response, 4 partial responses and 2 dogs experienced stable disease for an overall disease control rate of 64%). This includes one dog that experienced a complete response that has persisted for more than 1 year. Adverse effects were generally mild and self-limiting. In conclusion, VDC-1101 appears to have activity against canine CTCL, with a favorable adverse effect profile. One patient has experienced a complete and unusually durable response.
Help Future Generations of Dogs
Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.